Non-coding RNAs as clinical biomarkers for cancer diagnosis and prognosis

Expert Review of Molecular Diagnostics

Volumn 14, Issue 8, 2014, Pages 917-919

  Mishra, Prasun J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

biomarker; circulating microRNAs; diagnostics; microvesicles or exosomes; miRNA; miRNA polymorphisms; pharmacogenomics; precision medicine; prognosis; variants

Indexed keywords

BIOLOGICAL MARKER; DIHYDROFOLATE REDUCTASE; HISTONE DEACETYLASE 4; MICRORNA; MICRORNA 140; MICRORNA 200; MICRORNA 21; MICRORNA 215; MICRORNA 29A; SMALL UNTRANSLATED RNA; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; UNTRANSLATED RNA; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOMIC IN SITU HYBRIDIZATION; HUMAN; MOLECULAR DIAGNOSIS; NONHUMAN; PANCREAS CANCER; PATIENT MONITORING; RNA ANALYSIS; RNA SEQUENCE; TISSUE DISTRIBUTION; TREATMENT RESPONSE; GENETICS; NEOPLASMS; PROGNOSIS;

BIOMARKERS, TUMOR; HUMANS; NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; RNA, UNTRANSLATED;

EID: 84911893001     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.971761     Document Type: Article

References (25)

1. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6(11):857-66
2. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99(24): 15524-9
3. Mishra PJ, Merlino G. MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest 2009;119(8):2119-23
4. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008;110(1):13-21
5. Ohshima K, Inoue K, Fujiwara A, et al. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One 2010;5(10):e13247
6. Sieuwerts AM, Mostert B, Bolt-de Vries J, et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res 2011;17(11): 3600-18
7. Jones CI, Zabolotskaya MV, King AJ, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer 2012;107(12): 1987-96
8. Aushev VN, Zborovskaya IB, Laktionov KK, et al. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS One 2013;8(10):e78649
9. Camacho L, Guerrero P, Marchetti D. MicroRNA and protein profiling of brain metastasis competent cell-derived exosomes. PLoS One 2013;8(9):e73790
10. Cheng HH, Mitchell PS, Kroh EM, et al. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One 2013;8(7):e69239
11. Jones K, Nourse JP, Keane C, et al. Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. Clin Cancer Res 2014;20(1):253-64
12. Challagundla KB, Fanini F, Vannini I, et al. microRNAs in the tumor microenvironment: solving the riddle for a better diagnostics. Expert Rev Mol Diagn 2014;14(5):565-74
13. Fabbri M, Paone A, Calore F, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci USA 2012;109(31): E2110-16
14. Kan CW, Hahn MA, Gard GB, et al. Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer 2012;12:627
15. Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, et al. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med 2012;10:186
16. Sempere LF. Recent advances in miRNA-based diagnostic applications. Expert Rev Mol Diagn 2012;12(6):557-9
17. Sempere LF, Korc M. A method for conducting highly sensitive microRNA in situ hybridization and immunohistochemical analysis in pancreatic cancer. Methods Mol Biol 2013;980:43-59
18. Song B, Wang Y, Titmus MA, et al. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010;9:96
19. Karaayvaz M, Pal T, Song B, et al. Prognostic significance of miR-215 in colon cancer. Clin Colorectal Cancer 2011;10(4): 340-7
20. Weng L, Wu X, Gao H, et al. MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J Pathol 2010;222(1):41-51
21. Wu X, Weng L, Li X, et al. Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One 2012;7(5):e35661
22. Mishra PJ, Humeniuk R, Mishra PJ, et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci USA 2007;104(33):13513-8
23. Mishra PJ, Song B, Mishra PJ, et al. MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS One 2009; 4(12):e8445
24. Mishra PJ. The miRNA-drug resistance connection: a new era of personalized medicine using noncoding RNA begins. Pharmacogenomics 2012;13(12):1321-4
25. Mishra PJ. MicroRNA polymorphisms: a giant leap towards personalized medicine. Per Med 2009;6(2):119-25